DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Verapamil and Catamenial Epilepsy

Information source: University Health Network, Toronto
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Catamenial Epilepsy

Intervention: verapamil hyrochloride (Drug)

Phase: N/A

Status: Withdrawn

Sponsored by: University Health Network, Toronto

Official(s) and/or principal investigator(s):
Danielle Andrade, MD, Principal Investigator, Affiliation: College of Physicians and Surgeons of Ontario

Summary

One in 3 epilepsy patients have refractory seizures. This drug resistance is likely related to the over expression of multidrug resistance proteins (MDR). Progesterone is a known inhibitor of MDRs and the low level of this hormone during the menstrual cycle may exacerbate seizures, perhaps explaining catamenial epilepsy; i. e. seizures occurring during the menstrual cycle. Verapamil suppresses seizures in animal models of epilepsy perhaps by inhibiting MDRs and thus may help patients with refractory seizures. If the study shows improved seizure control, the results will help establish the role of MDRs in refractory epilepsy.

Clinical Details

Official title: Study of Verapamil in Refractory Catamenial Epilepsy

Study design: Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: the percent reduction in seizure frequency

Eligibility

Minimum age: 18 Years. Maximum age: 60 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- females

- at least 2 seizures per month

- more than 50% of the seizures occur 7 days before or 7 days after the onset of menses

- patient of the Toronto Western Hospital Epilepsy Clinic

Exclusion Criteria:

- cardiovascular history

Locations and Contacts

Toronto Western Hospital, Toronto, Ontario M5T 2S8, Canada
Additional Information

Starting date: February 2009
Last updated: April 7, 2010

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017